The Importance of NAD in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The etiology of multiple sclerosis (MS) is unknown but it manifests as a chronic inflammatory demyelinating disease in the central nervous system (CNS). During chronic CNS inflammation, nicotinamide adenine dinucleotide (NAD) concentrations are altered by (T helper) Th1-derived cytokines through the coordinated induction of both indoleamine 2,3-dioxygenase (IDO) and the ADP cyclase CD38 in pathogenic microglia and lymphocytes. While IDO activation may keep auto-reactive T cells in check, hyper-activation of IDO can leave neuronal CNS cells starving for extracellular sources of NAD. Existing data indicate that glia may serve critical functions as an essential supplier of NAD to neurons during times of stress. Administration of pharmacological doses of non-tryptophan NAD precursors ameliorates pathogenesis in animal models of MS. Animal models of MS involve artificially stimulated autoimmune attack of myelin by experimental autoimmune encephalomyelitis (EAE) or by viral-mediated demyelination using Thieler's murine encephalomyelitis virus (TMEV). The Wld(S) mouse dramatically resists razor axotomy mediated axonal degeneration. This resistance is due to increased efficiency of NAD biosynthesis that delays stress-induced depletion of axonal NAD and ATP. Although the Wld(S) genotype protects against EAE pathogenesis, TMEV-mediated pathogenesis is exacerbated. In this review, we contrast the role of NAD in EAE versus TMEV demyelinating pathogenesis to increase our understanding of the pharmacotherapeutic potential of NAD signal transduction pathways. We speculate on the importance of increased SIRT1 activity in both PARP-1 inhibition and the potentially integral role of neuronal CD200 interactions through glial CD200R with induction of IDO in MS pathogenesis. A comprehensive review of immunomodulatory control of NAD biosynthesis and degradation in MS pathogenesis is presented. Distinctive pharmacological approaches designed for NAD-complementation or targeting NAD-centric proteins (SIRT1, SIRT2, PARP-1, GPR109a, and CD38) are outlined towards determining which approach may work best in the context of clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“Block et al [302] proposed that microglia activation and neuronal damage can lead to progressive neurodegeneration, regardless of the instigating stimuli.”
BackgroundIdo expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“The idea of IDO mediated increases in proliferation is consistent with both the observations of the NAD precursor tryptophan as a lymphocyte mitogen as well as the well known observation that cancer cells are notorious in their over-expression of IDO [319-321].”
ResultLin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775 · cited 1×
“Originally, the Sirtuins came into the limelight when yeast sir2 was identified as playing central roles in controlling caloric restriction (CR) mediated increases in lifespan [238].”
BackgroundMammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation
Lombard, D. B., Alt, F. W., Cheng, H.-L., Bunkenborg, J., Streeper, R. S., Mostoslavsky, R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01636-07 · Cited by 1,216 · cited 3×
“SIRT3 is now known to be a master regulator controlling ATP generation [119] and global acetylation in the mitochondria [120].”
BackgroundApoptosis and delayed degeneration after spinal cord injury in rats and monkeys
Crowe, M. J., Bresnahan, J. C., Shuman, S. L., Masters, J. N., & Beattie, M. S. (1997) · Nature Medicine · doi:10.1038/nm0197-73 · Cited by 1,153
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“This is partly because a human clinical trial of IFNγ has been reported to exacerbate MS [65,66].”
BackgroundMuller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 1×
“The idea of IDO mediated increases in proliferation is consistent with both the observations of the NAD precursor tryptophan as a lymphocyte mitogen as well as the well known observation that cancer cells are notorious in their over-expression of IDO [319-321].”
ResultIncreased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060 · cited 14×
“Significantly, Wang et al showed that immediate benefit could be derived in axons by the addition of NAD (5 or 20mM) or the NAD precursor nicotinamide (5 or 25mM) in a SIRT1 independent fashion.”
BackgroundInfluentialDisruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination
Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P. E., Griffiths, I. R., & Nave, K.-A. (2003) · Nature Genetics · doi:10.1038/ng1095 · Cited by 1,036 · cited 1×
“Mouse mutants that lack expression of either PLP or 2',3'-cyclic nucleotide phosphodiesterase (CNP) have normal myelin sheaths, despite the fact that PLP and CNP are expressed exclusively in oligodendrocytes in the CNS [299].”
BackgroundRevollo, J. R., Grimm, A. A., & Imai, S.-I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408388200 · Cited by 1,010
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 2×
“Further, this was shown to involve a marked reduction in microglia activation [277].”
BackgroundNampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911 · cited 1×
“Already beneficial phenomena have been demonstrated for this precursor in the context of diabetes [226].”
BackgroundEvolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862 · cited 2×
“First, CD38 is highly expressed in the afflicted and pathogenic tissues of the MS of brain and lymphocytes respectively (for a review [151]).”
BackgroundActivity-dependent regulation of energy metabolism by astrocytes: an update
Pellerin, L., Bouzier‐Sore, A., Aubert, A., Serres, S., Merle, M., Costalat, R., & Magistretti, P. J. (2007) · Glia · doi:10.1002/glia.20528 · Cited by 805 · cited 1×
“Neurons receiving lactate from glia can immediately use lactate to generate both pyruvate and NADH for ATP generation [50, 51].”
BackgroundBieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
Resveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723 · cited 2×
“Resveratrol strongly promotes neurite outgrowth in Neuro2a cells in a SIRT1 independent but AMPK-dependent fashion [245].”
BackgroundThe genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · cited 1×
“Dementia results from neurodegeneration most commonly from Alzheimer’s Disease followed by vascular dementia [344].”
BackgroundAbsence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646 · cited 1×
“C57BL/WldS (Wallerian degeneration slow mutant, originally described as C57BL/6/ Ola) (WldS) mice, are a substrain of C57BL/6 (B6) mice [85].”
BackgroundWallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene
Mack, T. G. A., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001) · Nature Neuroscience · doi:10.1038/nn770 · Cited by 611
Tissue-specific regulation of SIRT1 by calorie restriction
Chen, D., Bruno, J., Easlon, E., Lin, S.-J., Cheng, H.-L., Alt, F. W., & Guarente, L. (2008) · Genes & Development · doi:10.1101/gad.1650608 · Cited by 567
Monitoring tryptophan metabolism in chronic immune activation
Schröcksnadel, K., Wirleitner, B., Winkler, C., & Fuchs, D. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.013 · Cited by 551 · cited 3×
“During autoimmune diseases [122] including MS [10, 140], the levels of tryptophan are dramatically depressed likely primarily due to increases in IDO expression that are used by the body to dampen the autoimmune response.”
BackgroundHDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis
Tall, A. R., Yvan-Charvet, L., Terasaka, N., Pagler, T., & Wang, N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.001 · Cited by 540
Tryptophan metabolism in the central nervous system: medical implications
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000068 · Cited by 519 · cited 1×
“Of likely significance to MS pathogenesis, the efficiency de novo and salvage NAD pathways is different in glia compared to neurons [35].”
BackgroundDror, D. K., & Allen, L. H. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2008.00031.x · Cited by 473
Kamanna, V. S., & Kashyap, M. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.029 · Cited by 453 · cited 1×
“Ultimately, target genes affected by nicotinic acid administration include CETP [200, 201], CD36 [202], ABCA1 [202], LXR [203], and many others [204].”
BackgroundSirt1 contributes critically to the redox-dependent fate of neural progenitors
Prozorovski, T., Schulze-Topphoff, U., Glumm, R., Baumgart, J., Schröter, F., Ninnemann, O., Siegert, E., Bendix, I., Brüstle, O., Nitsch, R., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1700 · Cited by 451 · cited 1×
“Recently, SIRT1 was determined to play a critical role in the fate specification decision for neural stem cells (NSCs; [251, 252]).”
BackgroundSirT1 Regulates Energy Metabolism and Response to Caloric Restriction in Mice
Boily, G., Seifert, E. L., Bevilacqua, L., He, X. H., Sabourin, G., Estey, C., Moffat, C., Crawford, S., Saliba, S., Jardine, K., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001759 · Cited by 444 · cited 2×
“More recently SIRT1 function has been shown to be required for CR mediated increases in mammalian lifespan [16].”
BackgroundAxonal Control of Oligodendrocyte Development
Barres, B. A., & Raff, M. C. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.6.1123 · Cited by 360 · cited 1×
“In clinical and experimental spinal cord injury and the optic nerve during the developmental period, oligodendrocyte apoptosis follows along the transected degenerated axons [84, 292-294].”
BackgroundA local mechanism mediates NAD-dependent protection of axon degeneration
Wang, J., Zhai, Q., Chen, Y., Lin, E., Gu, W., McBurney, M. W., & He, Z. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504028 · Cited by 352 · cited 12×
“However, Wang et al revealed that NAM considerably delayed Wallerian degeneration when supplied at higher concentrations of 5-25 mM [37].”
BackgroundInfluentialBlockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitis
Piccio, L., Buonsanti, C., Mariani, M., Cella, M., Gilfillan, S., Cross, A. H., Colonna, M., & Panina‐Bordignon, P. (2007) · European Journal of Immunology · doi:10.1002/eji.200636837 · Cited by 284 · cited 1×
“Inhibition of TREM-2 exacerbates EAE [345].”
Sasaki, Y., Araki, T., & Milbrandt, J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2320-06.2006 · Cited by 269
Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T., & Tsuchiya, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610357200 · Cited by 205 · cited 1×
“Hara et al [199], discovered that NAPRT is not inhibited by NAD.”
BackgroundGlucocorticoid hormones and early brain development in schizophrenia
Ph.D., J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00396-7 · Cited by 199 · cited 1×
“Nonetheless, consistent with such regulatory relationship, schizophrenics have elevated cortisol levels [134] and TDO2 levels [20, 135], where the long-term effect may be result in neurodegeneration.”
BackgroundTsunoda, I., & Fujinami, R. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199606000-00001 · Cited by 184
Self-citationPartida-Sanchez, S., Gasser, A., Fliegert, R., Siebrands, C. C., Dammermann, W., Shi, G., Mousseau, B. J., Sumoza-Toledo, A., Bhagat, H., Walseth, T. F., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7827 · Cited by 144 · cited 3×
“The roles of NAD depleting enzymes in the immune system are increasingly being appreciated, while the potential for NAD as a second messenger stimulating the persistent release of intracellular calcium to control lymphocyte chemotaxis [137] or microglia activation [138, 139].”
BackgroundMinocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage
Morimoto, N., Shimazawa, M., Yamashima, T., Nagai, H., & Hara, H. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.062 · Cited by 137 · cited 1×
“Similar to the application of NAD itself [48, 173], minocycline provides tremendous protection from focal ischemia [276, 277].”
BackgroundTsunoda, I., Kuang, L., Theil, D. J., & Fujinami, R. S. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00272.x · Cited by 86
Self-citationModels of multiple sclerosis: new insights into pathophysiology and repair
Lassmann, H. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282fee94a · Cited by 81
Cited by
The dynamic regulation of NAD metabolism in mitochondria
Stein, L. R., & Imai, S.-I. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.005 · Cited by 535
CNS inflammation and neurodegeneration
Chitnis, T., & Weiner, H. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90609 · Cited by 470
CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
Piedra-Quintero, Z. L., Wilson, Z., Nava, P., & Guerau-de-Arellano, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.597959 · Cited by 332
Energy metabolism in adult neural stem cell fate
Rafalski, V. A., & Brunet, A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.10.007 · Cited by 282
Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., Grant, R., & Sachdev, P. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7269 · Cited by 275
Metadata
- Authors
- Penberthy, W., & Tsunoda, I.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-01-01
- Volume
- 15
- Issue
- 1
- Pages
- 64-99
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2008933430
- Cited by
- 75
- References
- 39
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.